Resorcinol

Resorcinol

SCHEMBL458917

CCCCCc1c[nH]nc1CCCCC.Oc1cccc(O)c1

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 6/20 0.45
CYP3A4 P08684 3/20 0.45
TYR P14679 2/20 0.45
MAPT P10636 2/20 0.45
MEN1 O00255 1/20 0.45
TP53 P04637 1/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
HTT P42858 1/20 0.45
KMT2A Q03164 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
PTGS2 P35354 7/20 0.42
KDM4E B2RXH2 1/20 0.38
USP2 O75604 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
HPGD P15428 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL370841 0.84 TDP1 (0.35) ALOX5CYP3A4TYRMAPTMEN1
SCHEMBL27671187 0.83 LIPG (0.38) ALOX5CYP3A4TYRMAPTMEN1
SCHEMBL28300224 0.83 LIPG (0.38) ALOX5CYP3A4TYRMAPTMEN1
SCHEMBL28300226 0.83 LIPG (0.38) ALOX5CYP3A4TYRMAPTMEN1
Bromide SCHEMBL28162683 0.81 LIPG (0.37) ALOX5CYP3A4TYRMAPTMEN1
Bromide SCHEMBL28162087 0.81 LIPG (0.37) ALOX5CYP3A4TYRMAPTMEN1
Bromide SCHEMBL28162693 0.81 LIPG (0.37) ALOX5CYP3A4TYRMAPTMEN1
Pyrrole SCHEMBL28216728 0.80 ALOX5 (0.34) ALOX5TDP1PTGS2
SCHEMBL7016897 0.79 HRH3 (0.38) TYRALDH1A1
SCHEMBL6264510 0.77 HCAR2 (0.35) ALOX5CYP3A4TDP1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220184217-A1 HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF Fusion Pharmaceuticals Inc. (CA) 2022-06-16 US disclosed
EP-3946320-A1 HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF Tarveda Therapeutics, Inc. (US) 2022-02-09 EP disclosed
US-11241500-B2 HSP90-targeting conjugates and formulations thereof TARVEDA THERAPEUTICS, INC. (US) 2022-02-08 US disclosed
US-20220031853-A1 HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF TVA (ABC), LLC 2022-02-03 US disclosed
WO-2021202830-A2 HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF TARVEDA THERAPEUTICS, INC. (US) 2021-10-07 WO disclosed
EP-3849546-A1 HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF Tarveda Therapeutics, Inc. (US) 2021-07-21 EP disclosed
US-20210145971-A1 HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF Fusion Pharmaceuticals Inc. (CA) 2021-05-20 US disclosed
EP-3773670-A1 HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF Tarveda Therapeutics, Inc. (US) 2021-02-17 EP disclosed
US-20210000966-A1 HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF TVA (ABC), LLC 2021-01-07 US disclosed
CN-112074288-A HSP 90-targeting conjugates and formulations thereof 塔弗达治疗有限公司 2020-12-11 CN disclosed
WO-2012084602-A1 ARYL TRIAZOLE COMPOUNDS WITH ANTITUMOURAL ACTIVITY SIGMA-TAU RESEARCH SWITZERLAND S.A. (CH) 2012-06-28 WO disclosed
US-20120022026-A1 METHOD OF TREATING CANCER ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) 2012-01-26 US disclosed
EP-2387403-A1 METHOD OF TREATING CANCER Academisch Medisch Centrum bij de Universiteit van Amsterdam (NL) 2011-11-23 EP disclosed
US-20110253692-A1 Electrical heater for vehicle windshields and windows SCHAUBLE RICHARD EGON 2011-10-20 US disclosed
US-20110245221-A1 ARYL ISOXAZOLE COMPOUNDS WITH ANTITUMOURAL ACTIVITIES SIGMA-TAU RESEARCH SWITZERLAND S.A. (CH) 2011-10-06 US disclosed
EP-2310377-A1 5-PHENYL-ISOXAZOLE-3-CARBOXAMIDES MODULATING HSP90 WITH ANTITUMORAL ACTIVITIES SIGMA-TAU Research Switzerland S.A. (CH) 2011-04-20 EP disclosed
CN-101983191-A Oxim derivatives as hsp90 inhibitors TAKEDA PHARMACEUTICAL 2011-03-02 CN disclosed
WO-2010082821-A1 METHOD OF TREATING CANCER ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) 2010-07-22 WO disclosed
WO-2010082813-A1 METHOD OF TREATING CANCER ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) 2010-07-22 WO disclosed
WO-2010000748-A1 5-PHENYL-ISOXAZOLE-3-CARBOXAMIDES MODULATING HSP90 WITH ANTITUMORAL ACTIVITIES SIGMA-TAU RESEARCH SWITZERLAND S.A. (CH) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210000966-A1 HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF HSP90AB1, HSP90AA1, HSP90B1 ALOX5 4753/4885CYP3A4 4155/4885TYR 4109/4885
US-20220184217-A1 HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF HSP90AB1, HSP90B1, HSP90AA1 ALOX5 4741/4885CYP3A4 3955/4885TYR 4433/4885
US-20110245221-A1 ARYL ISOXAZOLE COMPOUNDS WITH ANTITUMOURAL ACTIVITIES HSP90AB1, HSP90AB2P, HSP90AA1 ALOX5 2495/4885CYP3A4 1796/4885TYR 434/4885
US-11241500-B2 HSP90-targeting conjugates and formulations thereof HSP90AB1, HSP90AA1, HSP90B1 ALOX5 4753/4885CYP3A4 4155/4885TYR 4109/4885
US-20220031853-A1 HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF HSP90AB1, HSP90AA1, HSP90B1 ALOX5 4753/4885CYP3A4 4155/4885TYR 4109/4885
US-20210145971-A1 HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF HSP90AB1, HSP90B1, HSP90AA1 ALOX5 4744/4885CYP3A4 4007/4885TYR 4326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.